<section class="s_text_block o_colored_level o_half_screen_height o_we_force_no_transition" data-name="Text" style="background-image: none;">
<h3><img class="img-fluid o_we_custom_image" src="/web/image/17255-f2ed4e1e/Banner1.png?access_token=e0ee1b07-de1f-47af-9567-035ccd5cf6b9" alt="" data-original-id="17255" data-original-src="/web/image/17255-f2ed4e1e/Banner1.png" data-mimetype="image/png" data-bs-original-title="" title="" aria-describedby="tooltip257911" style="width: 100% !important;" loading="lazy"><br></h3><h4>Cross-Regional Pitch &amp; Match session: Next generation vaccines &amp; immunotherapy</h4><p>The objective of this event is to connect important actors in the field of immunology, vaccinology, oncology and immunotherapy <strong style="font-weight: bolder">from Flanders and Wallonia or even abroad</strong>.</p><h4>Topic addressed?</h4><p>The topic of the event is <strong style="font-weight: bolder">Next generation vaccines &amp; immunotherapy, </strong>highlighting advances and innovations in recent vaccine and immunotherapy development. Vaccine platform technologies, broad-spectrum vaccines, new biomarker identification tools, better vaccine delivery systems, etc. will all help to prevent us from existing and future emerging pathogens. But also approved immune checkpoint inhibitors (ICIs) and cellular therapies like chimeric antigen receptor (CAR) T cells and tumor-infiltrating lymphocyte (TIL) therapy, as well as other modalities, such as oncolytic virus therapy are driving the next generation of immunotherapies for oncology, immune disorders and rare diseases.</p><p>During this networking afternoon, high quality <strong style="font-weight: bolder">presentations, including an informative talk of VLAIO/SPW/Innoviris explaining the interregional R&amp;D collaboration programme BELCOO,</strong> and <strong style="font-weight: bolder">pitches of our member network </strong>will be followed by a <strong style="font-weight: bolder">B2B partnering</strong> session.</p><p>This means that presenters can directly harvest the fruits of their talk or pre-schedule meetings with potential partners via the networking tool - powered by B2Match!<br></p><h4>Interested in pitching?</h4><p>Do you have expertise within the field of vaccine development, immunotherapy in human or animal health that contributes to the development of next generation vaccines and immunotherapy? Then here’s your <strong style="font-weight: bolder">opportunity to</strong> <strong style="font-weight: bolder">take the floor and present</strong> your expertise to an audience of potential partners.<br></p><p>Complete the <strong style="font-weight: bolder"><a href="https://forms.gle/CJRLc6kScNv8X7cJ7" target="_blank">Call for abstract template</a></strong> before <strong style="font-weight: bolder">April 28, 2023 </strong>(12 PM), describing your expertise that can be of interest for the development of innovative vaccines and immunotherapeutics.</p><p>A committee of the BioWin – Flanders Vaccine team will review all applications and inform you about the selection of the pitches in the first week of May.</p><h4>What’s in it for you?</h4><ul><li>You'll have the opportunity to present your project to an audience of interested partners</li><li>You gain additional visibility during the B2B session of the event</li><li>You can take advantage of the BELCOO programme that stimulates cross-border collaborations</li></ul><p>We’re looking forward to meet you at this occasion and don’t hesitate to contact us if you have any questions.</p><p><a class="btn btn-primary" href="https://pitch-match.b2match.io/">Register here</a></p><p><strong>Flanders Vaccine</strong></p><p>Fran Van Heuverswyn<br>Project Manager Flanders Vaccine<br><a href="mailto:fran.vanheuverswyn@flandersvaccine.be" target="_blank">fran.vanheuverswyn@flandersvaccine.be</a><br><br><strong>BioWin</strong></p><p>Alexandra Schiettekatte<br>Head of Communications BioWin<br><a href="mailto:alexandra.schiettekatte@biowin.org" target="_blank">alexandra.schiettekatte@biowin.org</a> </p></section>